MTOR and hepatocellular carcinoma: The conventional immunosuppressant drugs or calcineurin inhibitors (CNI) (Cyclosporine and Tacrolimus) have been associated with a dose-dependent increase in the risk of tumor recurrence after OLT [12, 13], compared with mTOR inhibitors-based immunosuppression (Sirolimus and Everolimus) which have been associated with increased survival of patients undergoing OLT for HCC [14, 15].